



RON CHAPMAN, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

DATE: August 15, 2013 IZB-FY-1213-17

TO: Vaccines for Children (VFC) Providers

FROM: Maria Volk, M.P.A., Acting Chief *Maria E. Volk*
Center for Infectious Diseases
Division of Communicable Disease Control, Immunization Branch

SUBJECT: Pediarix[®] and Sanofi Pasteur Vaccine[®] Supply Update

PEDIARIX[®] VACCINE SUPPLY AND ORDERING UPDATE

Pediarix[®] Vaccine Supply

The California Vaccines for Children (VFC) Program has been notified by the Centers for Disease Control and Prevention (CDC) that supplies of Pediarix[®] (DTaP-IPV-HepB) have improved. The limit on VFC Program's monthly Pediarix[®] allocation has been lifted. Providers may now begin ordering Pediarix[®] supplies to meet their patient needs for the full 3-dose series.

Provider Supplies of Individual DTaP, Hepatitis B, and IPV Vaccines

In order to prevent unnecessary vaccine waste due to expiration (also considered a negligent vaccine loss), providers using Pediarix[®] should continue to use their current inventories of individual DTaP, hepatitis B, and IPV vaccines for booster immunization. Vaccine supplies should be monitored and vaccine doses reordered, as appropriate. Viable unused doses of these individual vaccines CANNOT be returned to the VFC Program.

All Pediarix[®] vaccine requests must include complete inventory of these individual vaccine components on hand. Providers with significant doses of single vaccine components on-hand that they cannot use solely as booster doses should reduce their inventory prior to increasing orders of Pediarix.

SANOFI PASTEUR VACCINE SUPPLY AND ORDERING UPDATE

Sanofi notified CDC today that several of their products will be in limited supply through October. The impacted products are Pentacel®, Daptacel® (DTaP), and Adacel® (Tdap).

Pentacel®

No additional doses of Pentacel® are being released to states until at least mid-October. The VFC Program will notify providers when Pentacel® will again be available for ordering.

Daptacel®

Supplies will be limited through August and then no additional doses will be released until at least mid-October. The VFC program continues to have adequate supplies of other DTaP products.

Adacel®

Supplies will be limited through mid-October. It is unclear exactly how many doses will be available to California at this point, but it is likely that orders will need to be reduced until supply is back to normal. Providers will have the ability to order GSK's Boostrix®.

ActHib®

In addition, due to the current Pentacel® supply situation, the CDC has instituted limited allocation during the month of August for ActHIB®. Current allocated doses for California appear sufficient based on average vaccine distribution data, and no restriction for ActHIB® orders are in place at this time. Should this situation change, providers will be notified. The CDC anticipates that monthly allocations of ActHIB® will not extend beyond August.

The VFC Program continues to have adequate supplies of hepatitis B, and IPV vaccines to meet provider demand.

We appreciate your flexibility, understanding, and your continued efforts to immunize our young children against serious vaccine preventable diseases. If you have any questions about this communication, please contact your VFC Representative or VFC Customer Service at 1-877-243-8832.

cc: CDPH Immunization Branch Field Representatives
Local Health Officers
Local Health Department Immunization Coordinators
Local Health Department CHDP Program Directors
Margaret Tatar, Chief, Medi-Cal Managed Care Division, DHCS
Susan McClair, M.D., Medi-Cal Managed Care, DHCS
Shabbir Ahmad, D.V.M., M.S., Ph.D., Acting Chief, Maternal, Child and Adolescent

Pediarix® and Pentacel® Supply Update

Page 3 of 3

August 15, 2013

Health Program, CDPH

Laurie Weaver, Chief, Office of Family Planning, CDPH

Shelley Rouillard, Deputy Director, Benefits and Quality Monitoring Division,
MRMIB

Emmee Nguyen, Benefits and Quality Monitoring, MRMIB

Brett Williams, M.D. Medical Policy Section, Medi-Cal Benefits, Waiver Analysis
and Rates Division, DHCS

Alan Morita, Pharm.D. Medi-Cal Pharmacy Policy Branch, DHCS

Robert Dimand, M.D., Chief, Children Medical Services Branch, DHCS

Jill Abramson, M.D., M.P.H., Children Medical Services Branch, DHCS

Dave Hubbard, Refugee Health Assessment Program, CDPH

Marisa Ramos, Ph.D., Chief, Refugee Health Assessment Program, CDPH

Karen Tracy, R.N., M.S., Indian Health Program, DHCS

Sandra (Sam) Willburn, Chief, Primary and Rural Health Division, DHCS